Observations placeholder

Temsirolimus (CCI-779) is an intravenous drug for the treatment of renal cell carcinoma (RCC),  and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative and prodrug of sirolimus and is sold as Torisel.

Adverse reactions

The toxicity profile is based on what was found in the phase III trial

• adverse reaction
  • fatigue
  • skin rash
  • stomatitis
• hematologic abnormalities
  • hemoglobin decreased
  • lymphocytes decreased
• laboratory abnormalities
  • triglycerides increased
  • glucose increased
  • phosphorus decreased

Temsirolimus has been generally well tolerated in clinical settings by patients with advanced RCC. In patients with RCC, the adverse effect profile of temsirolimus is primarily metabolic in nature, with minimal impact on QoL compared with the commonly seen side-effects with oral multikinase inhibitors. Temsirolimus’ high level of specificity for mTOR likely contributes to the tolerability of temsirolimus. However, temsirolimus increases mortality in cancer patients

On Feb, 13, 2016: 2,078 people reported to have side effects when taking Torisel. Among them, 18 people (0.77%) have Hallucination.

Time on Torisel when people have Hallucination  :

On Feb, 3, 2016: 2,078 people reported to have side effects when taking Torisel. Among them, 95 people (4.57%) have Death.

Time on Torisel when people have Death  :

Age of people who have Death when taking Torisel  :

Top conditions involved for these people  :

1. Renal cell carcinoma (24 people, 25.26%)
2. Metastatic renal cell carcinoma (20 people, 21.05%)